https://andro.io/app/recist
Power 100
Android app profile
MeVis RECIST 1.1 for Android – Latest Version & Features
★★★★★
(0 ratings)
Rate this app
How do you feel about MeVis RECIST 1.1?
Thanks for your feedback!
> 2.2k
Monthly Downloads
~$900
Estimated Cost
Screenshots
About MeVis RECIST 1.1
The MeVis RECIST 1.1 app supports medical staff in oncology, radiology or general medicine and students of human medicine in evaluating the therapeutic response in the treatment of solid tumors according to the guidelines of RECIST 1.1.Details• RECIST (Response Evaluation Criteria In Solid Tumors / criteria for evaluating the response to treatment in solid tumors) helps in therapy monitoring through a standardized evaluation of tumor sums.
This allows treatment results to be objectified in oncology and other teams involved.• The MeVis RECIST 1.1 app is not a medical product.Functions• The high-speed calculator allows - depending on the type of lesion - the quick assessment of several measured values in comparison.• The rule section lists all rules according to RECIST 1.1 in a clear and comprehensible manner.
In addition, the pocket card with all RECIST 1.0 and 1.1 features can be downloaded and used.thanksgiving• The MeVis RECIST 1.1.
App was developed in collaboration with PD Dr.
T.
Persigehl (University Hospital Cologne), Dr.
S.
Lennartz (University Hospital Cologne), Dr.
M.
Völker (DRG), the Oncology Working Group of the German Radiological Society and MeVis Medical Solutions AG.
This allows treatment results to be objectified in oncology and other teams involved.• The MeVis RECIST 1.1 app is not a medical product.Functions• The high-speed calculator allows - depending on the type of lesion - the quick assessment of several measured values in comparison.• The rule section lists all rules according to RECIST 1.1 in a clear and comprehensible manner.
In addition, the pocket card with all RECIST 1.0 and 1.1 features can be downloaded and used.thanksgiving• The MeVis RECIST 1.1.
App was developed in collaboration with PD Dr.
T.
Persigehl (University Hospital Cologne), Dr.
S.
Lennartz (University Hospital Cologne), Dr.
M.
Völker (DRG), the Oncology Working Group of the German Radiological Society and MeVis Medical Solutions AG.